GSO ISO 25539-2:2016
ISO 25539-2:2012
Gulf Standard
Current Edition
·
Approved on
22 December 2016
Cardiovascular implants -- Endovascular devices -- Part 2: Vascular stents
GSO ISO 25539-2:2016 Files
English
92 Pages
Current Edition
Reference Language
103.01 OMR
GSO ISO 25539-2:2016 Scope
1.1 This part of ISO 25539 specifies requirements for vascular stents, based upon current medical knowledge. With regard to safety, it gives requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization, packaging and information supplied by the manufacturer. It should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants.
NOTE Due to the variations in the design of implants covered by this part of ISO 25539 and in some cases due to the relatively recent development of some of these implants (e.g. bioabsorbable stents, polymeric stents), acceptable standardized in vitro tests and clinical results are not always available. As further scientific and clinical data become available, appropriate revision of this part of ISO 25539 will be necessary.
1.2 The scope of this part of ISO 25539 includes vascular stents used to treat vascular lesions or stenoses, or other vascular abnormalities. These devices might or might not incorporate surface modifications of the stent such as drug and/or other coatings. Stents covered with materials that significantly modify the permeability of the uncovered stent are within the scope of ISO 25539-1. The stent design might dictate the need to address functional requirements identified in both ISO 25539-1 and this part of ISO 25539.
1.3 Delivery systems are included in this part of ISO 25539 if they comprise an integral component of the deployment of the vascular stent.
1.4 Procedures and devices used prior to the introduction of the vascular stent, such as balloon angioplasty devices, are excluded from the scope of this part of ISO 25539.
1.5 Some pharmacological aspects of drug-eluting stents are addressed in this part of ISO 25539, but this part of ISO 25539 is not comprehensive with respect to the pharmacological evaluation of drug-eluting stents.
1.6 Degradation and other time-dependent aspects of bioabsorbable and polymeric stents and coatings are not addressed by this part of ISO 25539.
1.7 With the exception of sterilization, this part of ISO 25539 does not address requirements for the evaluation of animal tissue products.
Best Sellers From Health Sector
GSO 2017:2023
Gulf Standard
Personal Care and Baby Wet Wipes

GSO 2241:2023
Gulf Standard
Cosmetic Products - Body Cleaners

GSO 2063:2023
Gulf Standard
Cosmetic Products - Hair Conditioner (Balsam)

GSO 1223:2023
Gulf Standard
Cosmetic Products-Deodorants

Recently Published from Health Sector
GSO ISO 11608-7:2024
ISO 11608-7:2016
Gulf Standard
Needle-based injection systems for medical use
— Requirements and test methods
— Part 7: Accessibility for persons with visual impairment


GSO ISO/TR 24666:2024
ISO/TR 24666:2023
Gulf Standard
Sports and recreational facilities
— Probes for entrapment/entanglement on playground equipment
— Collection of data


GSO ISO 9713:2024
ISO 9713:2022
Gulf Standard
Neurosurgical implants
— Self-closing intracranial aneurysm clips


GSO ISO/TS 22690:2024
ISO/TS 22690:2021
Gulf Standard
Genomics informatics
— Reliability assessment criteria for high-throughput gene-expression data

